In this study of healthy women, we therefore investigated the eff

In this study of healthy women, we therefore investigated the effects of prucalopride on the pharmacokinetics

of the estrogen ethinylestradiol and the progestogen norethisterone, which are the active constituents of several oral contraceptives. 2 Methods 2.1 Study Design This randomized, open-label, two-way crossover, phase I trial ( identifier: NCT01036893) was designed to evaluate both the effect of single-dose prucalopride 2 mg (Resolor®;1 prucalopride succinate tablets) on the absorption of ethinylestradiol and norethisterone, and the effect of 5 or 6 days of treatment with prucalopride 2 mg once daily on the steady-state pharmacokinetics of ethinylestradiol and norethisterone in healthy women. The trial was carried out at a single center in Germany (FOCUS Clinical Drug Development GmbH, Neuss, Germany) from December 17, 2009, until February 10, 2010, in accordance with the Declaration of Helsinki and the International Conference

on Harmonisation Good Clinical Practice guidelines [13, 14], and was approved by the relevant independent ethics committees. All participants provided written informed consent before screening. 2.2 Participants Eligibility was assessed Palbociclib nmr at a screening visit, which took place within the 4 weeks before the first drug administration. Healthy women (in the age group of 18–45 years) who had regular menstrual cycles of 28 ± 3 days in the previous 6 months were eligible for inclusion in the study if they had a body mass index (BMI) of 18–27 kg/m2; had not smoked in the 6 months before screening; and were using adequate non-hormonal

birth control such as the double-barrier method (e.g. a condom and spermicide, a cervical cap and spermicide), were practicing MRIP abstinence, or had a partner who was sterile (e.g. had undergone vasectomy). Individuals were excluded from the study if they had a history or evidence of drug or alcohol abuse; had abnormal electrocardiogram (ECG) intervals or morphology (e.g. QT interval >500 ms or corrected QT interval using Bazett’s formula [QTcB] >470 ms) that were considered to be clinically significant; had a history or evidence of cardiac arrhythmias, bronchospastic disease, or cardiovascular disease; or had a history or evidence of psychiatric, gynecological, hepatic, gastrointestinal, renal, endocrine, neurological, or dermatological disease. Individuals with drug allergies, those who had contraindications for the use of oral contraceptives (e.g. known or suspected active venous thromboembolic disorders, hormone-dependent malignancies, coagulation disorders, menstrual cycle-dependent migraines, lipid metabolism disorders, or hepatic disorders), and those who had used other medications, oral contraceptives, or any hormonal depot device in the 6 months before screening were also excluded.

Comments are closed.